中等剂量卡培他滨单药治疗转移性乳腺癌的疗效及安全性

目的观察中等剂量［2 000 mg/(m²·d)］卡培他滨治疗转移性乳腺癌的疗效和不良反应。方法卡培他滨单药治疗43例转移性乳腺癌，2000 mg/(m²·d),d1～14,每3周为1周期。结果43例患者平均行8周期卡培他滨治疗，客观缓解率（CR+PR）为18.6%，临床获益率（CR+PR+SD）为86.0%。整体的中位无进展生存期（PFS）为7.1月（95%CI：5.8～8.4），在一线治疗、二线治疗和三线及以上治疗亚组中差异无统计学意义，分别为7.1月、6.1月和8.1月（P=0.390）。在蒽环类药物与紫杉类药物治疗均失败的患者中，PFS明显缩短（6.1月 vs.7.1月，P=0.038）。大于65岁的患者PFS显著延长（8.1月 vs.6.1月，P=0.045）。主要不良反应为手足综合征19例（44.2%）。结论中等剂量［2 000 mg/(m²·d)］卡培他滨单药治疗转移性乳腺癌安全、有效。

Efficacy and Safety of Moderate-dose Capecitabine in Treatment of Metastatic Breast Cancer

Objective To determine activity and safety of capecitabine at a moderate dose of 2000mg/(m2.d)for metastatic breast cancer.Methods In this retrospective trial,43metastatic breast cancer patients received first-line capecitabine 2 000mg/m2 on days 1～14every 3weeks.Results 43metastatic breast cancer patients received mean 8cycles of capecitabine therapy.Median PFS was 7.1months(95% CI:5.8～8.4).There were no difference among the first line,the second line and third line treatment 7.1 months,6.1months,and 8.1months respectively(P=0.390).Patients pretreated with both anthracycline and taxane therapy had a significantly shorter PFS(6.1months vs.7.1months,P=0.038),but patients>65years achieved a significantly longer PFS(8.1months vs.6.1months,P=0.045).Ninteen cases(44.2%)had hand-foot syndrome,a main toxicity.Conclusion Capecitabine at a moderate dose of 2 000mg/(m2.d)is active and well-tolerated for metastatic breast cancer.